ArticleInternational ophthalmology2026
Analysing ocular structural morbidities in younger adults using anti-seizure drugs: a cross-sectional study.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe primary treatment for managing epilepsy consists of anti-seizure drugs (ASDs). Nevertheless, their prolonged use has been associated with various ocular complications. The structural alterations, such as thinning of the retinal nerve fiber layer (RNFL) and macular edema, have received limited research attention in younger adults undergoing extended ASD treatment.
objectiveThis study aimed to evaluate the structural and functional changes in the eyes specifically, refractive error, tear film quality, macular health, and RNFL thickness among young adults who are on long-term ASD therapy.
methodsA cross-sectional investigation involved 340 subjects aged between 20 and 40, comprising 200 ASD users and 140 healthy controls matched by age. All participant underwent a thorough ocular assessment that included best-corrected visual acuity (BCVA), subjective refraction, intraocular pressure, Schirmer's I & II tests, tear breakup time (TBUT), slit-lamp examination, fundus photography, and Optical Coherence Tomography (OCT) for analysis of the retinal nerve fibre layer (RNFL) and macula. The statistical evaluation was conducted using the Kruskal-Wallis H test, with significance established at P < 0.05.
resultsUsers of ASD exhibited a significantly higher average refractive error (-2.50DS/ ± 1.00DC) compared to controls (-0.75DS/ ± 0.75DC180). Tear metrics were considerably lower, with Schirmer's I & II and TBUT demonstrating significant disparities in sodium valproate users (P < 0.001). OCT findings indicated early signs of macular edema in 10% of ASD users, particularly among those on sodium valproate and topiramate. RNFL thickness displayed an average reduction of 8.5 µm relative to controls (P = 0.042), with the most pronounced thinning noted in users of lamotrigine and levetiracetam.
conclusionProlonged ASD treatment is linked to observable changes in ocular structure, including dry eye disease, myopia, macular edema, and RNFL thinning. These outcomes highlight the necessity for routine ophthalmic evaluation and collaborative care to prevent irreversible visual impairment in individuals with epilepsy.
Indexed as
Identifiers
41591611What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.